Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostatic Cancer”

331 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 331 results

Testing effectiveness (Phase 2)Study completedNCT00040586
What this trial is testing

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

Who this might be right for
Prostatic Neoplasms
BZL Biologics
Testing effectiveness (Phase 2)Ended earlyNCT01093183
What this trial is testing

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer
University of Nebraska 25
Testing effectiveness (Phase 2)Study completedNCT00450619
What this trial is testing

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 44
Large-scale testing (Phase 3)Study completedNCT00364455
What this trial is testing

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Who this might be right for
ProstateCarcinoma
Janssen-Ortho Inc., Canada 56
Not applicableStudy completedNCT00002924
What this trial is testing

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

Who this might be right for
Prostate Cancer
Alliance for Clinical Trials in Oncology 184
Testing effectiveness (Phase 2)Study completedNCT00411528
What this trial is testing

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Novartis Pharmaceuticals 185
Large-scale testing (Phase 3)Study completedNCT00036556
What this trial is testing

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Abbott 941
Testing effectiveness (Phase 2)Study completedNCT01487720
What this trial is testing

GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Asan Medical Center 33
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Early research (Phase 1)Study completedNCT01144897
What this trial is testing

PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy

Who this might be right for
Castrate Resistant Prostate CancerProstate Cancer
Daniel Vaena 5
Early research (Phase 1)Looking for participantsNCT05997615
What this trial is testing

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Who this might be right for
Hormone-refractory Prostate Cancer
Astellas Pharma Global Development, Inc. 437
Large-scale testing (Phase 3)Study completedNCT00065442
What this trial is testing

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Who this might be right for
Prostate Cancer
Dendreon 512
Testing effectiveness (Phase 2)Study completedNCT00629525
What this trial is testing

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
Daniel George, MD 35
Testing effectiveness (Phase 2)Study completedNCT00005810
What this trial is testing

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
Alliance for Clinical Trials in Oncology 40
Testing effectiveness (Phase 2)Study completedNCT00286793
What this trial is testing

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

Who this might be right for
Prostate Cancer
Ascenta Therapeutics 76
Testing effectiveness (Phase 2)Study completedNCT00286806
What this trial is testing

Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
Ascenta Therapeutics 27
Testing effectiveness (Phase 2)Study completedNCT00257478
What this trial is testing

The Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Who this might be right for
Prostate CancerCancer of ProstateProstatic Cancer+1 more
Astellas Pharma Inc
Testing effectiveness (Phase 2)UnknownNCT00003717
What this trial is testing

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
St. Barnabas Medical Center 17
Large-scale testing (Phase 3)Study completedNCT00127478
What this trial is testing

A Long Term Safety Study With Atrasentan

Who this might be right for
Prostate CancerAdenocarcinoma
Abbott 166
Testing effectiveness (Phase 2)Study completedNCT00327340
What this trial is testing

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Who this might be right for
Prostate Cancer
Achieve Life Sciences 70
Next Page